Eloralintide
NCT06230523
Eli Lilly · Phase 2 · Completed · Enrollment 263
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Placebo, one timepoint
- 1 mg Eloralintide, one timepoint
- 3 mg Eloralintide, one timepoint
- 6 mg Eloralintide, one timepoint
- 9 mg Eloralintide, one timepoint
- Placebo: week 48 -0.4%
- 1 mg Eloralintide: week 48 -9%
- 3 mg Eloralintide: week 48 -12%
- 6 mg Eloralintide: week 48 -18%
- 9 mg Eloralintide: week 48 -20%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.